Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Single-Dose Bioequivalence Study of Injections of Lebrikizumab Using a 2-mL Pre-Filled Syringe With Needle Safety Device and an Investigational 2-mL Autoinjector in Healthy Participants
Conditions
Interventions
Lebrikizumab
Locations
4
United States
LabCorp CRU, Inc.
Daytona Beach, Florida, United States
QPS
Springfield, Missouri, United States
Covance Dallas
Dallas, Texas, United States
LabCorp CRU, Inc.
Madison, Wisconsin, United States
Start Date
June 2, 2021
Primary Completion Date
February 11, 2022
Completion Date
February 11, 2022
Last Updated
November 22, 2024
NCT07310264
NCT00090662
NCT06716502
NCT06290258
NCT07483606
NCT06342713
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions